Further prospective clinical trials are required to analyse the long-term effectiveness of omalizumab or other anti-IgE monoclonal antibodies (e.g. ligelizumab and quilizumab) in ABPA.106. This evidence concerns the gene IGHE and allergic bronchopulmonary aspergillosis.